In the future, BDNF may possibly be added as a newly available biomarker to the amyloid-tau-neurodegeneration (ATN) system developed by Jack Jr et al. in the National Institute on Aging and Alzheimer’s Association (NIA-AA) Research Framework that is widely used to diagnose AD that, not only focuses on cognitive staging, but also on any biomarkers changes in the AD continuum113. This evidence concerns the gene MAPT and Alzheimer disease.